SURMOUNT-5 Trial: Tirzepatide Beats Semaglutide 2.4mg Head-to-Head for Weight Loss

SURMOUNT-5: The Definitive Head-to-Head Showdown

The question that dominated obesity medicine for years — "Is tirzepatide or semaglutide better for weight loss?" — was answered definitively by the SURMOUNT-5 trial. Published in the New England Journal of Medicine in May 2025 by Aronne et al., this was the first randomized, head-to-head comparison of tirzepatide against semaglutide 2.4 mg (the full obesity dose) in adults without diabetes. The results were unequivocal: tirzepatide produced significantly greater weight loss [1].

Why This Trial Matters

Prior to SURMOUNT-5, the comparison between tirzepatide and semaglutide relied on cross-trial comparisons:

• SURMOUNT-1 (tirzepatide): 22.5% weight loss with 15 mg
• STEP 1 (semaglutide): 14.9% weight loss with 2.4 mg

While suggestive, cross-trial comparisons are unreliable due to differences in patient populations, trial design, and measurement methods. SURMOUNT-5 eliminated these confounders with a direct, randomized comparison.

Additionally, the earlier SURPASS-2 trial compared tirzepatide against semaglutide 1 mg (the diabetes dose), not the higher 2.4 mg obesity dose. SURMOUNT-5 used the maximum approved doses of both drugs [1].

Study Design

SURMOUNT-5 was a 72-week, open-label, randomized Phase 3b trial:

• Population: 751 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidity) without type 2 diabetes
• Randomization: 1:1 to tirzepatide (up to 15 mg) or semaglutide (up to 2.4 mg)
• Duration: 72 weeks
• Primary Endpoint: Percent change in body weight at week 72
• Key Secondary Endpoints: Proportion achieving ≥5%, ≥10%, ≥15%, ≥20%, ≥25% weight loss

Both drugs followed their standard dose-escalation protocols:

• Tirzepatide: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (escalating every 4 weeks)
• Semaglutide: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (escalating every 4 weeks)

Primary Results: Tirzepatide Wins Decisively

Mean Percent Change in Body Weight at 72 Weeks:

• Tirzepatide: -20.2%
• Semaglutide 2.4 mg: -13.7%
• Treatment difference: -6.5 percentage points (P<0.001 for superiority)

Tirzepatide produced 47% greater weight loss than semaglutide — a clinically enormous difference [1].

Categorical Weight Loss Thresholds

The categorical results further highlighted tirzepatide's advantage:

At the ≥20% threshold — a level approaching bariatric surgery outcomes — tirzepatide nearly doubled semaglutide's success rate. More than one in three tirzepatide patients lost ≥25% of their body weight [1].

Waist Circumference

Tirzepatide also produced significantly greater reduction in waist circumference:

• Tirzepatide: -18.5 cm
• Semaglutide: -13.5 cm
• Difference: -5.0 cm (P<0.001)

Waist circumference is a key indicator of visceral fat, which is more metabolically harmful than subcutaneous fat. The greater waist reduction suggests tirzepatide may preferentially reduce visceral adiposity [1].

Safety Comparison

The safety profiles were broadly similar:

Gastrointestinal Events:

• Nausea: Similar rates between groups
• Diarrhea: Similar rates
• Vomiting: Similar rates
• Constipation: Similar rates

Discontinuation due to adverse events:

• Tirzepatide: ~6%
• Semaglutide: ~4%

Serious adverse events:

• Similar rates between groups
• No new safety signals for either drug

Notably, despite producing significantly greater weight loss, tirzepatide did not have meaningfully higher rates of adverse events. The GI side effect profiles were comparable, suggesting that the dual GIP/GLP-1 mechanism achieves greater efficacy without proportionally increasing side effects [1].

Why the 6.5% Difference Matters

A 6.5 percentage point difference in weight loss is clinically significant for several reasons:

1. Absolute weight: For a 100 kg patient, this translates to 6.5 kg (14.3 lbs) more weight loss
2. Comorbidity resolution: Greater weight loss is associated with higher rates of diabetes remission, hypertension resolution, and sleep apnea improvement
3. Surgical threshold: More patients cross the 20-25% threshold where outcomes approach bariatric surgery
4. Patient satisfaction: Greater weight loss improves body image, quality of life, and treatment adherence

The Dual Agonist Advantage Confirmed

SURMOUNT-5 provides the strongest evidence yet that the dual GIP/GLP-1 mechanism is superior to GLP-1 alone:

GIP's Contribution:

• Enhanced fat oxidation and energy expenditure
• Improved adipose tissue metabolism
• Synergistic appetite suppression with GLP-1
• Potential metabolic benefits independent of weight loss

The consistent ~6-7 percentage point advantage of tirzepatide over semaglutide across multiple trials (SURPASS-2 for diabetes, SURMOUNT-5 for obesity) suggests this is a real and reproducible effect of the dual mechanism [2].

Clinical Decision-Making

For clinicians choosing between tirzepatide and semaglutide:

Favor Tirzepatide When:

• Maximum weight loss is the primary goal
• Patient has both obesity and type 2 diabetes
• Patient has not achieved adequate weight loss on semaglutide
• Approaching bariatric surgery-level weight loss is desired

Favor Semaglutide When:

• Proven cardiovascular benefit is desired (SELECT trial data)
• Oral formulation is preferred (oral semaglutide available)
• Insurance coverage favors semaglutide
• Patient has tolerated and responded well to semaglutide

References

1. Aronne LJ, Sattar N, Horn DB, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." New England Journal of Medicine. 2025. PubMed: 40353578

2. Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine. 2021;385(6):503-515. PubMed: 34170647

3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216. PubMed: 35658024